Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The business of developing antibacterials

Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: Vancomycin-resistant enterococci.

Centers for Disease Control and Prevention/Janice Car

Figure 2: Market for systemic antibacterials.
Figure 3: Antibacterial agents approved 1983–2007.


  1. Moore, A. The big and small of drug discovery. Biotech versus pharma: advantages and drawbacks in drug development. EMBO Reports 4, 114–117 (2003).

    Article  CAS  Google Scholar 

  2. Mygind, P.H. et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437, 975–980 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fox, J. The business of developing antibacterials. Nat Biotechnol 24, 1521–1528 (2006).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing